Latest Ratios: P/E Ratio -22.4x · EV/EBITDA N/A · ROE -105.2%. (2022–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Market Cap | $1.9B | $1.6B | — | — | — |
| Enterprise Value | $1.9B | $1.6B | — | — | — |
| P/E Ratio → | -22.44 | — | — | — | — |
| P/S Ratio | — | — | — | — | — |
| P/B Ratio | 5.49 | 5.36 | — | — | — |
| P/FCF | — | — | — | — | — |
| P/OCF | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — |
| EV / FCF | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — |
| Operating Margin | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| ROE | -105.2% | -105.2% | — | — | — |
| ROA | -29.4% | -29.4% | -51.9% | -67.9% | -46.1% |
| ROIC | -204.4% | -204.4% | — | — | — |
| ROCE | -36.4% | -36.4% | -64.4% | -81.8% | -52.3% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Debt / Equity | 0.03 | 0.03 | — | — | — |
| Debt / EBITDA | — | — | — | — | — |
| Net Debt / Equity | — | -0.16 | — | — | — |
| Net Debt / EBITDA | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — |
| Interest Coverage | — | — | — | — | — |
Net cash position: cash ($58M) exceeds total debt ($9M)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Current Ratio | 20.61 | 20.61 | 14.49 | 4.88 | 10.16 |
| Quick Ratio | 20.61 | 20.61 | 14.49 | 4.88 | 10.16 |
| Cash Ratio | 20.14 | 20.14 | 14.16 | 4.79 | 10.01 |
| Asset Turnover | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — |
| FCF Yield | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | — | — | — |
| Shares Outstanding | — | $40M | $44M | $44M | $44M |
Clinical trial execution failure
As reported in financial statements, Sionna’s P/B ratio of 5.49 reflects an innovation premium typical of clinical-stage biotech, yet the negative TTM P/E of -22.44 underscores the speculative nature of its valuation in the absence of any commercial revenue streams or established earnings power.
The current valuation appears to be driven entirely by the market's assessment of the NBD1 stabilization platform rather than fundamental financial metrics. Investors should monitor whether this premium holds as the company approaches critical data readouts, as any clinical setback could lead to a rapid compression of the P/B multiple.
Based on the company's reported figures, the ROIC has fluctuated significantly, reaching -9.1% in 2026Q1, which highlights the ongoing challenge of generating positive returns on invested capital while the firm remains in a high-intensity, pre-revenue clinical development phase without any operational margin support.
The negative ROIC trend suggests that capital is being consumed at a rate that far outpaces the current value creation of the R&D pipeline. This trajectory warrants investigation into whether the company's capital allocation strategy can eventually pivot toward efficiency once clinical milestones are achieved.
According to recent SEC filings, Sionna maintains a current ratio of 22.60, which appears superficially robust but is misleading given the company's lack of revenue and the persistent, high-velocity cash burn required to fund its ongoing clinical trials and research operations.
While the high current ratio suggests an ability to meet short-term obligations, the lack of recurring cash inflows means this liquidity is finite and rapidly depleting. Investors should monitor the quarterly burn rate closely, as the current cash position provides only a limited window for operational success before further dilution becomes necessary.
As indicated by the company's financial data, the current ratio of 22.60 is frequently misapplied by analysts to suggest financial strength, when in reality, it merely reflects the temporary holding of capital raised through equity, obscuring the underlying reality of a business model that is structurally cash-burning.
For a pre-revenue biotech firm, the current ratio is a poor proxy for financial health because it does not account for the lack of operational cash generation. A more appropriate metric for this business model would be the 'cash runway' in months, which provides a clearer picture of the time remaining before the company must return to capital markets.
Includes 30+ ratios · 4 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying SION stock.
Sionna Therapeutics, Inc.'s current P/E ratio is -22.4x. This places it at the 50th percentile of its historical range.
Sionna Therapeutics, Inc.'s return on equity (ROE) is -105.2%. The historical average is -105.2%.
Based on historical data, Sionna Therapeutics, Inc. is trading at a P/E of -22.4x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.